ClinConnect ClinConnect Logo
Search / Trial NCT06877988

Artificial Intelligence (AI) - Assisted Visual Impairment Screening Model: Community-based Implementation and Evaluation of Performance, Feasibility and Costs.

Launched by SINGAPORE EYE RESEARCH INSTITUTE · Mar 10, 2025

Trial Information

Current as of April 26, 2025

Recruiting

Keywords

Visual Impairment Community Screening Randomized Controlled Trial (Rct) Artificial Intelligence (Ai)

ClinConnect Summary

This clinical trial is studying a new way to check for vision problems using artificial intelligence (AI). The goal is to see if this AI-assisted screening can do a better job at finding visual impairments compared to the traditional methods we currently use. Researchers want to find out if the AI model not only improves the accuracy of screenings but also makes the process faster and more cost-effective for healthcare providers in the community.

To participate in this study, you must be 50 years old or older. If you join, you will have your vision checked using either the AI-assisted method or the traditional one. After the screening, you'll have a chance to share your thoughts on how acceptable and easy the process was for you. This study is currently looking for participants, and your involvement could help improve how we screen for vision issues in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Individuals aged 50 years old and above.
  • Exclusion Criteria:
  • Individuals aged below 50 years old.

About Singapore Eye Research Institute

The Singapore Eye Research Institute (SERI) is a leading clinical research organization dedicated to advancing the understanding and treatment of eye diseases. As a collaborative institute affiliated with the National University of Singapore and the Singapore Health Services, SERI focuses on innovative research and clinical trials that aim to improve patient outcomes in ophthalmology. With a multidisciplinary team of experts, SERI is committed to translating scientific discoveries into effective therapies and enhancing the quality of eye care through rigorous research initiatives and community engagement.

Locations

Singapore, , Singapore

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported